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Supplemental Table 1. International Classification of Diseases codes, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes used in the study 
ICD-9-CM codes Descriptions 
Atrial fibrillation 
427.3 Atrial fibrillation and flutter 
  Valvular heart diseases/replacement or hyperthyroidism 
242 Thyrotoxicosis with or without goitre 
394.0 Mitral stenosis 
  Valvular heart surgery (procedure codes) 
35.20 Open and other replacement of unspecified heart valve 
35.22 Open and other replacement of aortic valve 
35.24 Open and other replacement of mitral valve 
35.26 Open and other replacement of pulmonary valve 
35.28 Open and other replacement of tricuspid valve 
  Transient atrial fibrillation 
Cardiac surgery (procedure codes) 
00.5 Other cardiovascular procedures 
35 Operations on valves and septa of heart 
36 Operations on vessels of heart 
37 Other operations on heart and pericardium 
  Pericarditis 
391 Rheumatic fever with heart involvement 
393 Chronic rheumatic pericarditis 
420 Acute pericarditis 
423.2 Constrictive pericarditis 
036.41 Meningococcal pericarditis 
074.21 Coxsackie pericarditis 
093.81 Syphilitic pericarditis 
098.83 Gonococcal pericarditis 
  Myocarditis 
130.3 Myocarditis due to toxoplasmosis 
391.2 Acute rheumatic myocarditis 
398.0 Rheumatic myocarditis 
422 Acute myocarditis 
429.0 Myocarditis, unspecified 
032.82 Diphtheritic myocarditis 
036.43 Meningococcal myocarditis 
074.23 Coxsackie myocarditis 
093.82 Syphilitic myocarditis 
  Pulmonary embolism 
415.1 Pulmonary embolism and infarction 
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Supplemental Table 1. International Classification of Diseases codes, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes used in the study (continued) 
ICD-9-CM codes Descriptions 
Congestive Heart Failure 
398.91 Rheumatic heart failure (congestive)  
402.01 Malignant hypertensive heart disease with heart failure 
402.11 Benign hypertensive heart disease with heart failure 
402.91 Unspecified hypertensive heart disease with heart failure 
404.01 
Hypertensive heart and chronic kidney disease, malignant, with heart failure 
and with chronic kidney disease stage I through stage IV, or unspecified 
404.03 
Hypertensive heart and chronic kidney disease, malignant, with heart failure 
and with chronic kidney disease stage V or end stage renal disease 
404.11 
Hypertensive heart and chronic kidney disease, benign, with heart failure and 
with chronic kidney disease stage I through stage IV, or unspecified 
404.13 
Hypertensive heart and chronic kidney disease, benign, with heart failure and 
chronic kidney disease stage V or end stage renal disease  
404.91 
Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and with chronic kidney disease stage I through stage IV, or 
unspecified  
404.93 
Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and chronic kidney disease stage V or end stage renal disease 
428 Heart failure 
  Hypertension 
401 Essential hypertension 
402 Hypertensive heart disease  
403 Hypertensive chronic kidney disease  
404 Hypertensive heart and chronic kidney disease  
405 Secondary hypertension 
437.2 Hypertensive encephalopathy 
  Diabetes 
 250 Diabetes mellitus 
  Ischaemic stroke 
433.01 Occlusion and stenosis of basilar artery with cerebral infarction   
433.11 Occlusion and stenosis of carotid artery with cerebral infarction   
433.21 Occlusion and stenosis of vertebral artery with cerebral infarction   
433.31 
Occlusion and stenosis of multiple and bilateral precerebral arteries with 
cerebral infarction   
433.81 
Occlusion and stenosis of other specified precerebral artery with cerebral 
infarction 
433.91 
Occlusion and stenosis of unspecified precerebral artery with cerebral 
infarction 
434 Occlusion of cerebral arteries   
436 Acute, but ill-defined, cerebrovascular disease 
437.0 Cerebral atherosclerosis   
437.1 Other generalized ischemic cerebrovascular disease   
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Supplemental Table 1. International Classification of Diseases codes, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes used in the study (continued) 
ICD-9-CM codes Descriptions 
Transient ischaemic attack 
435 Transient cerebral ischemia   
  Systemic embolism 
444  Arterial embolism and thrombosis 
445 Atheroembolism 
  
Vascular disease 
410-414 Ischemic heart disease 
443.8 Other specified peripheral vascular diseases 
443.9 Peripheral vascular disease, unspecified 
  
Myocardial infarction 
410 Acute myocardial infarction 
412 Old myocardial infarction 
  Intracranial haemorrhage 
430 Subarachnoid haemorrhage 
431 Intracerebral haemorrhage 
432 Other and unspecified intracranial haemorrhage 
  Gastrointestinal bleeding 
531.0 Acute gastric ulcer with hemorrhage 
531.2 
Acute gastric ulcer with hemorrhage and perforation, without mention of 
obstruction 
531.4 Chronic or unspecified gastric ulcer with hemorrhage 
531.6 Chronic or unspecified gastric ulcer with hemorrhage and perforation 
532.0 Acute duodenal ulcer with hemorrhage 
532.2 Acute duodenal ulcer with hemorrhage and perforation 
532.4 Chronic or unspecified duodenal ulcer with hemorrhage 
532.6 Chronic or unspecified duodenal ulcer with hemorrhage and perforation 
533.0 Acute peptic ulcer of unspecified site with hemorrhage 
533.2 Acute peptic ulcer of unspecified site with hemorrhage and perforation 
533.4 Chronic or unspecified peptic ulcer of unspecified site with hemorrhage 
533.6 
Chronic or unspecified peptic ulcer of unspecified site with hemorrhage and 
perforation 
534.0 Acute gastrojejunal ulcer with hemorrhage 
534.2 
Acute gastrojejunal ulcer with hemorrhage and perforation, without mention 
of obstruction 
534.4 Chronic or unspecified gastrojejunal ulcer with hemorrhage 
534.6 Chronic or unspecified gastrojejunal ulcer with hemorrhage and perforation 
535.01 Acute gastritis, with hemorrhage 
535.11 Atrophic gastritis, with hemorrhage 
535.21 Gastric mucosal hypertrophy, with hemorrhage 
535.31 Alcoholic gastritis, with hemorrhage 
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Supplemental Table 1. International Classification of Diseases codes, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes used in the study (continued) 
ICD-9-CM codes Descriptions 
Gastrointestinal bleeding [continued] 
535.41 Other specified gastritis, with hemorrhage 
535.51 Unspecified gastritis and gastroduodenitis, with hemorrhage 
535.61 Duodenitis, with hemorrhage 
535.71 Eosinophilic gastritis, with hemorrhage  
562.02 Diverticulosis of small intestine with hemorrhage 
562.03 Diverticulitis of small intestine with haemorrhage 
562.12 Diverticulosis of colon with haemorrhage 
562.13 Diverticulitis of colon with haemorrhage 
569.3 Hemorrhage of rectum and anus 
569.85 Angiodysplasia of intestine with haemorrhage 
569.86 Dieulafoy lesion (hemorrhagic) of intestine 
578.0 Hematemesis 
578.1 Melena 
578.9 Hemorrhage of gastrointestinal tract, unspecified 
  Other bleeding 
423.0 Hemopericardium 
459.0 Haemorrhage NOS 
593.81 Vascular disorders of kidney 
599.7 Haematuria 
623.8 Other specified noninflammatory disorders of vagina 
626.2 Excessive menstruation 
626.6 Metrorrhagia 
719.1 Hemarthrosis 
784.7 Epistaxis 
784.8 Haemorrhage from throat 
786.3 Haemoptysis 
  Renal disease  
403 Hypertensive chronic kidney disease 
404 Hypertensive heart and chronic kidney disease 
580 Acute glomerulonephritis 
581 Nephrotic syndrome 
582 Chronic glomerulonephritis 
583 Nephritis and nephropathy not specified as acute or chronic 
584 Acute kidney failure 
585 Chronic kidney disease (ckd) 
586 Renal failure unspecified 
590.0 Chronic pyelonephritis 
753.1 Cystic kidney disease 
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Supplemental Table 1. International Classification of Diseases codes, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes used in the study (continued) 
ICD-9-CM codes Descriptions 
Fall 
781.2 Abnormality of gait 
781.3 Lack of coordination 
781.99 Other symptoms involving nervous and musculoskeletal systems 
V15.88 History of fall 
E880-E888 Accidental Falls 
  
Pneumonia  
486 Pneumonia, organism unspecified 
  
Charlson comorbidity index 
Myocardial infarction 
410 Acute myocardial infarction 
412 Old myocardial infarction 
  Congestive Heart Failure 
398.91 Rheumatic heart failure (congestive)  
402.01 Malignant hypertensive heart disease with heart failure 
402.11 Benign hypertensive heart disease with heart failure 
402.91 Unspecified hypertensive heart disease with heart failure 
404.01 Hypertensive heart and chronic kidney disease, malignant, with heart 
failure and with chronic kidney disease stage I through stage IV, or 
unspecified 
404.03 Hypertensive heart and chronic kidney disease, malignant, with heart 
failure and with chronic kidney disease stage V or end stage renal disease 
404.11 Hypertensive heart and chronic kidney disease, benign, with heart failure 
and with chronic kidney disease stage I through stage IV, or unspecified 
404.13 Hypertensive heart and chronic kidney disease, benign, with heart failure 
and chronic kidney disease stage V or end stage renal disease  
404.91 Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and with chronic kidney disease stage I through stage IV, or 
unspecified  
404.93 Hypertensive heart and chronic kidney disease, unspecified, with heart 
failure and chronic kidney disease stage V or end stage renal disease 
428 Heart failure 
  
Peripheral vascular disease 
441 Aortic aneurysm and dissection 
443.9 Peripheral vascular disease, unspecified 
785.4 Gangrene 
V43.4 Blood vessel replaced by other means 
  
Cerebrovascular disease 
430-438 Cerebrovascular disease 
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Supplemental Table 1. International Classification of Diseases codes, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes used in the study (continued) 
ICD-9-CM codes Descriptions 
Charlson comorbidity index [continued] 
Chronic obstructive pulmonary disease 
490-496 Chronic Obstructive Pulmonary Disease and Allied Conditions 
500 Coal workers' pneumoconiosis 
501 Asbestosis 
502 Pneumoconiosis due to other silica or silicates 
503 Pneumoconiosis due to other inorganic dust 
504 Pneumonopathy due to inhalation of other dust 
505 Pneumoconiosis, unspecified 
506.4 Respiratory conditions due to chemical fumes and vapors 
  
Dementia  
290 Dementias 
  
Paralysis  
342 Hemiplegia and hemiparesis 
344.1 Paraplegia 
  
Diabetes without chronic complication 
250.0 Diabetes mellitus without mention of complication 
250.1 Diabetes with ketoacidosis 
250.2 Diabetes with hyperosmolarity 
250.3 Diabetes with other coma 
250.7 Diabetes with peripheral circulatory disorders 
  
Diabetes with chronic complication 
250.4 Diabetes with renal manifestations 
250.5 Diabetes with ophthalmic manifestations 
250.6 Diabetes with neurological manifestations 
  
Chronic renal failure 
582 Chronic glomerulonephritis 
583.0 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
proliferative glomerulonephritis 
583.1 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
membranous glomerulonephritis 
583.2 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
membranoproliferative glomerulonephritis 
583.4 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
rapidly progressive glomerulonephritis 
583.6 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
renal cortical necrosis 
583.7 Nephritis and nephropathy, not specified as acute or chronic, with lesion of 
renal medullary necrosis 
585 Chronic kidney disease (ckd) 
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Supplemental Table 1. International Classification of Diseases codes, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes used in the study (continued) 
ICD-9-CM codes Descriptions 
Charlson comorbidity index [continued] 
Chronic renal failure [continued] 
586 Renal failure, unspecified 
588 Disorders resulting from impaired renal function 
  
Various cirrhodites 
571.2 Alcoholic cirrhosis of liver 
571.4 Chronic hepatitis 
571.5 Cirrhosis of liver without mention of alcohol  
571.6 Biliary cirrhosis 
  
Moderate-severe liver disease 
456.0 Esophageal varices with bleeding 
456.1 Esophageal varices without bleeding 
456.2 Esophageal varices in diseases classified elsewhere 
572.2 Hepatic encephalopathy 
572.3 Portal hypertension 
572.4 Hepatorenal syndrome 
572.8 Other sequelae of chronic liver disease 
  
Ulcers 
531 Gastric ulcer 
532 Duodenal ulcer 
533 Peptic ulcer site unspecified 
534 Gastrojejunal ulcer 
 
Rheumatoid arthritis and other inflammatory polyarthropathies 
710.0 Systemic lupus erythematosus 
710.1 Systemic sclerosis 
710.4 Polymyositis 
714.0 Rheumatoid arthritis 
714.1 Felty's syndrome 
714.2 Other rheumatoid arthritis with visceral or systemic involvement 
714.81 Rheumatoid lung 
725 Polymyalgia rheumatica 
  
Acquired Immune Deficiency Syndrome 
042 Human immunodeficiency virus [HIV] disease 
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Supplemental Table 1. International Classification of Diseases codes, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes used in the study (continued) 
ICD-9-CM codes Descriptions 
Charlson comorbidity index [continued] 
Malignancy  
140-149 Malignant neoplasm of lip, oral cavity, and pharynx 
150-159 Malignant neoplasm of digestive organs and peritoneum 
160-165 Malignant neoplasm of respiratory and intrathoracic organs 
170-172, 174-176 Malignant neoplasm of bone, connective tissue, and breast 
179-189 Malignant neoplasm of genitourinary organs 
190-195 Malignant neoplasm of other sites 
200-208 Malignant neoplasm of lymphatic and hematopoietic tissue 
  
Metastatic solid tumour 
196 Secondary and unspecified malignant neoplasm of lymph nodes 
197 Secondary malignant neoplasm of respiratory and digestive systems 
198 Secondary malignant neoplasm of other specified sites 
199 Malignant neoplasm without specification of site 
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Supplemental Table 2. Post hoc analyses with stratification for quality of anticoagulation control among warfarin users 
  
 
Before PS matching After PS matching 
  N 
No. of 
events 
Incidence/ 
100 py 
Crude 
IRR (95%CI) 
N 
No. of 
events 
Incidence/ 
100 py 
Adjusted 
IRR (95%CI)a 
Dabigatran 2325 122 3.9 0.84 (0.68-1.05) 1418 81 4.2 0.99 (0.70-1.40) 
Warfarin, Poor INR control 2622 240 4.7 Reference 1418 106 4.5 Reference 
 
   
     
Dabigatran 2325 122 3.9 1.13 (0.84-1.52) 548 24 3.2 1.20 (0.69-2.11) 
Warfarin, Good INR control 937 69 3.5 Reference 548 28 2.7 Reference 
Abbreviations: PS, propensity score; py, patient-years; IRR, incidence rate ratio; CI, confidence interval; INR, international normalized control. 
Poor INR control, time in therapeutic range<65%; Good INR control, time in therapeutic range≥65%. 
aIRR’s were obtained using zero-inflated negative binomial regression to account for excess zero counts in hospital admissions. 
 
  
11 
 
Supplemental Table 3. Incidence of hospital admission with bleeding for dabigatran 110 mg twice daily dosing 
  Before PS matching After PS matching 
 
Dabigatran 
(N=1992) 
Warfarin 
(N=5656) 
Dabigatran 
vs. Warfarin 
Dabigatran 
(N=1991) 
Warfarin 
(N=1991) 
Dabigatran 
vs. Warfarin 
Hospital admissions n 
Incidence/ 
100 py 
n 
Incidence/ 
100 py 
Crude  
IRR (95% CI) 
n 
Incidence/ 
100 py 
n 
Incidence/ 
100 py 
Adjusted  
IRR (95% CI)b 
All Bleeding 122 5.1 412 5.5 0.93 (0.76-1.14) 122 5.1 127 5.6 1.04 (0.71-1.54) 
   Gastrointestinal bleeding 72 3.0 145 1.9 1.58 (1.19-2.10)* 72 3.0 44 1.9 2.76 (1.43-5.33)* 
   Intracranial hemorrhage 13 0.5 104 1.3 0.40 (0.22-0.71)* 13 0.5 29 1.2 0.31 (0.12-0.77)* 
   Other bleedinga 42 1.7 188 2.5 0.70 (0.50-0.98)* 42 1.7 58 2.5 0.68 (0.43-1.09) 
Abbreviations: PS, propensity score; py, patient-years; IRR, incidence rate ratio; CI, confidence interval. 
aother bleeding includes epistaxis, haematuria, haemarthrosis, hemopericardium, haemoptysis, and hemorrhage from kidney, throat, and vagina. 
bIRR’s were obtained using zero-inflated negative binomial regression to account for excess zero counts in hospital admissions. 
*p<0.05.  
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Supplemental Table 4. Incidence of hospital admission with bleeding using different permissible medication gaps 
  Before PS matching After PS matching 
 
Dabigatran 
(n=2653) 
Warfarin 
(n=5656) 
Dabigatran 
vs. Warfarin 
Dabigatran 
(n=2580) 
Warfarin 
(n=2580) 
Dabigatran 
vs. Warfarin 
Hospital admissions n 
Incidence/ 
100 py 
n 
Incidence/ 
100 py 
Crude  
IRR (95% CI) 
n 
Incidence/ 
100 py 
n 
Incidence/ 
100 py 
Adjusted  
IRR (95% CI)b 
Medication gap=10 days           
   All Bleeding 158 4.8 447 5.4 0.89 (0.74-1.06) 156 4.9 184 5.8 0.89 (0.65-1.23) 
      Gastrointestinal bleeding 92 2.8 157 1.9 1.49 (1.15-1.93)* 91 2.8 68 2.1 2.09 (1.23-3.56)* 
      Intracranial hemorrhage 17 0.5 113 1.3 0.38 (0.23-0.64)* 16 0.5 45 1.4 0.28 (0.13-0.59)* 
      Other bleedinga 54 1.6 203 2.4 0.67 (0.50-0.90)* 54 1.7 80 2.5 0.62 (0.39-0.98)* 
           
Medication gap=20 days           
   All Bleeding 165 4.8 469 5.5 0.88 (0.74-1.05) 163 4.9 195 5.9 0.84 (0.62-1.14) 
      Gastrointestinal bleeding 94 2.7 167 1.9 1.42 (1.11-1.83)* 93 2.7 73 2.2 1.91 (1.14-3.19)* 
      Intracranial hemorrhage 19 0.5 122 1.4 0.39 (0.24-0.64)* 18 0.5 51 1.5 0.27 (0.14-0.55)* 
      Other bleedinga 57 1.6 212 2.4 0.67 (0.50-0.90)* 57 1.7 83 2.5 0.61 (0.39-0.95)* 
Abbreviations: PS, propensity score; py, patient-year; IRR, incidence rate ratio; CI, confidence interval. 
aother bleeding includes epistaxis, haematuria, haemarthrosis, hemopericardium, haemoptysis, and hemorrhage from kidney, throat, and vagina. 
bIRR’s were obtained using zero-inflated negative binomial regression to account for excess zero counts in hospital admissions. 
*p<0.05. 
 
 
  
13 
 
Supplemental Table 5. Post hoc analyses for patients aged<75 years and ≥75 years 
  Before PS matching 
 After PS matching  
 
Dabigatran 
(Age<75y: N=1252 
  Age≥75y: N=1401) 
Warfarin 
(Age<75y: N=3079 
  Age≥75y: N=2577) 
Dabigatran 
vs. Warfarin 
 Dabigatran 
(Age<75y: N=1235 
   Age≥75y: N=1315) 
Warfarin 
(Age<75y: N=1235 
  Age≥75y: N=1315) 
Dabigatran 
vs. Warfarin 
 
First 
admission with 
bleeding 
n 
Incidence/ 
100 py 
n 
Incidence/ 
100 py 
Crude IRR  
(95% CI) 
P for 
interaction 
n 
Incidence/ 
100 py 
n 
Incidence/ 
100 py 
Adjusted IRR  
(95% CI)a 
P for 
interaction 
    Age<75y 40 2.6 196 4.5 
0.58 
(0.41-0.82)* 
0.01 
39 2.5 63 4.2 
0.59  
(0.35-0.97)* 
0.02 
    Age≥75y 113 7.2 216 6.9 
1.04 
(0.83-1.31) 
106 7.2 92 6.4 
1.29  
(0.83-2.01) 
30-day  
re-admission 
with bleedingb 
n % n % 
HR 
(95% CI) 
P for 
interaction 
n % n % 
HR 
(95% CI) 
P for 
interaction 
    Age<75y 5/35 14.3 12/148 8.1 
1.63 
(0.55-4.81) 
0.33 
5/34 14.7 5/49 10.2 
1.39 
(0.38-5.03) 
0.77 
    Age≥75y 12/92 13.0 7/146 4.8 
3.36 
(1.28-8.79)* 
12/87 13.8 5/60 8.3 
1.79 
(0.62-5.21) 
Abbreviations: PS, propensity score; py, patient-years; IRR, incidence rate ratio; CI, confidence interval; HR, hazard ratio. 
aIRR’s were obtained using zero-inflated negative binomial regression to account for excess zero counts in hospital admissions. 
bValues are expressed as: number of patients re-hospitalized within 30 day of discharge/total number of hospitalized patients discharged during follow-up. 
*p<0.05.  
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Supplemental Table 6. 30-day re-admission with bleeding for dabigatran 110 mg twice daily dosing 
  Before PS matching After PS matching 
 
Dabigatran Warfarin 
Dabigatran 
vs. Warfarin 
Dabigatran Warfarin 
Dabigatran 
vs. Warfarin 
30-day re-admissions n % n % HR (95% CI) n % n % HR (95% CI) 
All Bleeding 13/102 12.7 19/294 6.5 1.99 (0.96-4.14) 13/102 12.7 5/89 5.6 2.15 (0.74-6.26) 
   Gastrointestinal bleeding 7/60 11.7 6/103 5.8 1.92 (0.64-5.78) 7/60 11.7 2/29 6.9 1.62 (0.34-7.80) 
   Intracranial hemorrhage 1/8 12.5 1/35 2.9 4.69 (0.29-75.7) 1/8 12.5 0/10 0 -b 
   Other bleedinga 4/37 10.8 11/172 6.4 1.87 (0.59-5.87) 4/37 10.8 3/53 5.7 2.07 (0.46-9.27) 
Abbreviations: PS, propensity score; HR, hazard ratio; CI, confidence interval. 
Values are expressed as: number of patients re-hospitalized within 30 day of discharge/total number of hospitalized patients. 
aother bleeding includes epistaxis, haematuria, haemarthrosis, hemopericardium, haemoptysis, and hemorrhage from kidney, throat, and vagina. 
bunable to estimate hazard ratio as there were no warfarin patients re-hospitalized with intracranial hemorrhage.  
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Supplemental Table 7. 30-day re-admission with bleeding using different permissible medication gaps 
  Before PS matching After PS matching 
 
Dabigatran Warfarin 
Dabigatran 
vs. Warfarin 
Dabigatran Warfarin 
Dabigatran 
vs. Warfarin 
30-day re-admissions n % n % HR (95% CI) n % n % HR (95% CI) 
Medication gap=10 days           
   All Bleeding 17/132 12.9 22/318 6.9 2.03 (1.06-3.92)* 17/131 13.0 7/126 5.6 2.57 (1.04-6.36)* 
      Gastrointestinal bleeding 7/77 9.1 6/111 5.4 1.58 (0.52-4.77) 7/76 9.2 2/45 4.4 1.90 (0.39-9.26) 
      Intracranial hemorrhage 2/10 20.0 2/37 5.4 3.29 (0.46-23.2) 2/10 20.0 0/13 0 -b 
      Other bleedinga 7/48 14.6 13/187 7.0 2.26 (0.90-5.67) 7/48 14.6 5/73 6.8 2.24 (0.71-7.06) 
           
Medication gap=20 days           
   All Bleeding 17/137 12.4 23/335 6.9 1.98 (1.03-3.77)* 17/136 12.5 7/130 5.4 2.55 (1.03-6.27)* 
      Gastrointestinal bleeding 7/78 9.0 6/118 5.1 1.68 (0.56-5.09) 7/77 9.1 2/47 4.3 2.04 (0.42-9.96) 
      Intracranial hemorrhage 2/11 18.2 2/42 4.8 3.35 (0.47-24.1) 2/11 18.2 0/14 0 -b 
      Other bleedinga 7/51 13.7 14/195 7.2 2.09 (0.84-5.17) 7/51 13.7 5/75 6.7 2.16 (0.69-6.82) 
Abbreviations: PS, propensity score; HR, hazard ratio; CI, confidence interval. 
Values are expressed as: number of patients re-hospitalized within 30 day of discharge/total number of hospitalized patients. 
aother bleeding includes epistaxis, haematuria, haemarthrosis, hemopericardium, haemoptysis, and hemorrhage from kidney, throat, and vagina. 
bunable to estimate hazard ratio as there were no warfarin patients re-hospitalized with intracranial hemorrhage.  
*p<0.05. 
 
